- Date: May 31, 2017
- Parc Científic de Barcelona
- Carrer de Baldiri Reixac, 4-12-15
- 08028 Barcelona
- show map
Biocat and CataloniaBIO organise “Lessons Learned: Innovation in technology transfer”, a conference to exchange information and knowledge between public centres and companies. The event, in which the Barcelona Science Park (PCB) and ACCIÓ collaborate, will be held on 31/05/17 from 4:00 p.m. to 7:30 p.m. at the Sala Dolors Aleu of the Clústers building where the Barcelona Science Park (PCB) is found.
During this meeting, participants will see how the transfer of technology and know-how from the public centres to the companies is promoted and how public-private collaborations work. They will share knowledge about innovative programmes to exploit technologies in academic centres. The programme will feature the following speakers:
- Moderated by: Felip Miralles – Director of the eHealth Unit, Eurecat.
- Gemma Torruella – Project & Programme Manager, Caixa Capital Risc.
- Francisco Moreno – Director of the Science and Technology Transfer Area, Fundación Botín.
- Carlos Plata – Chief Scientific Officer, Chief Medical Officer and Head of R&D, Esteve.
This conference is part of the series “Lessons Learned: Sharing experiences to increase competitiveness”, a forum for knowledge and networking aimed at professionals of companies in the life sciences field. The purpose of these meetings is to share experiences and reflections on different strategic areas of knowledge and acquire capabilities to improve the competitiveness of biotechnology companies.
Parc Científic de Barcelona, Barcelona
May 14, 2018
The conference programme includes presentations and networking opportunities, and last year featured participants from 24 different countries.
April 23, 2018
BioVaria allows transfer professionals and spin-offs to present their innovations to representatives from the pharmaceutical industry and potential investors.
April 23, 2018
The conference is a meeting point between innovative companies in the life sciences industry, executives from large pharmaceutical companies, and representatives from investment funds.